Reply to D. Tural et al

Blanchard, Pierre; Bourhis, Jean; Pignon, Jean-Pierre

doi:10.1200/jco.2013.53.5997

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47,48 A metaanalysis of the IC trials comparing cisplatin and 5-fluorouracil with or without taxane reported superior overall survival (HR, 0.79; 95% CI, 0.70-0.89; P<.001), progression-free survival (HR, 0.78; 95% CI, 0.60-0.87; P<.001), locoregional failure (HR, 0.79; 95% CI, 0.66-0.94; P¼.007), and distant failure (HR, 0.63; 95% CI, 0.45-0.89; P¼.009) for cisplatin, 5-fluorouracil, and taxane. 49 In the treatment of laryngeal cancer, sequential therapy was not found to be feasible in a phase 2 trial comparing docetaxel plus cisplatin and 5-fluorouracil induction followed by randomization to cisplatin and RT or cetuximab and RT. Both treatments were associated with substantial toxicity, and the dropout rate from severe or life-threatening toxicity encountered with induction docetaxel plus cisplatin and 5-fluorouracil was unacceptably high.…”

Section: Induction Chemotherapymentioning

confidence: 99%

Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment

Marur

Forastiere

2016

Mayo Clinic Proceedings

953

802

View full text Add to dashboard Cite

Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. The risk factors for development of cancers of the oral cavity, oropharynx, hypopharynx, and larynx include tobacco exposure and alcohol dependence, and infection with oncogenic viruses is associated with cancers developing in the nasopharynx, palatine, and lingual tonsils of the oropharynx. The incidence of human papillomavirus-associated oropharyngeal cancer is increasing in developed countries, and by 2020, the annual incidence could surpass that of cervical cancer. The treatment for early-stage squamous cell cancers of the head and neck is generally single modality, either surgery or radiotherapy. The treatment for locally advanced head and neck cancers is multimodal, with either surgery followed by adjuvant radiation or chemoradiation as indicated by pathologic features or definitive chemoradiation. For recurrent disease that is not amenable to a salvage local or regional approach and for metastatic disease, chemotherapy with or without a biological agent is indicated. To date, molecular testing has not influenced treatment selection in head and neck cancer. This review will focus on the changing epidemiology, advances in diagnosis, and treatment options for squamous cell cancers of the head and neck, along with data on risk stratification specific to oropharyngeal cancer, and will highlight the direction of current trials.

show abstract

Section: Induction Chemotherapymentioning

confidence: 99%